ID   NB-1643
AC   CVCL_5627
SY   NB1643; NB 1643
DR   BTO; BTO:0002833
DR   cancercelllines; CVCL_5627
DR   Cell_Model_Passport; SIDM01388
DR   Cosmic; 1161994
DR   Cosmic; 1890114
DR   DepMap; ACH-001303
DR   GEO; GSM2371243
DR   GEO; GSM2394390
DR   GEO; GSM4104583
DR   GEO; GSM4104584
DR   GEO; GSM4104630
DR   GEO; GSM4104631
DR   GEO; GSM4105318
DR   GEO; GSM4105319
DR   GEO; GSM4105320
DR   GEO; GSM4105321
DR   GEO; GSM4105322
DR   IARC_TP53; 23603
DR   Wikidata; Q54907501
RX   PubMed=9802058;
RX   PubMed=9815701;
RX   PubMed=18724359;
RX   PubMed=20922763;
RX   PubMed=23202128;
RX   PubMed=28350380;
WW   https://www.cccells.org/PDF_Files/NB_Cell_Lines/NB-1643%20Cell%20Line%20Data%20Sheet.pdf
WW   http://www.pptpinvitro.org/cell_lines_panel.php
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Doubling time: 43 hours (PubMed=20922763).
CC   Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (PubMed=18724359; PubMed=28350380; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058).
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: Deep exome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Retroperitoneal space; UBERON=UBERON_0003693.
ST   Source(s): DepMap; PubMed=20922763
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 12
ST   D16S539: 9,12
ST   D18S51: 12,15
ST   D19S433: 13,14
ST   D21S11: 28
ST   D2S1338: 23,24
ST   D3S1358: 16,18
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 14,16
ST   FGA: 22,23
ST   Penta D: 10
ST   Penta E: 7,11
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=9802058;
RA   McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A.,
RA   Harris L.C.;
RT   "Bax is an important determinant of chemosensitivity in pediatric
RT   tumor cell lines independent of Bcl-2 expression and p53 status.";
RL   Oncol. Res. 10:235-244(1998).
//
RX   PubMed=9815701;
RA   Thompson J., Zamboni W.C., Cheshire P.J., Lutz L., Luo X.-L., Li Y.-L.,
RA   Houghton J.A., Stewart C.F., Houghton P.J.;
RT   "Efficacy of systemic administration of irinotecan against
RT   neuroblastoma xenografts.";
RL   Clin. Cancer Res. 3:423-431(1997).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//